Ontario Teachers Pension Plan Board cut its holdings in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 29.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,477 shares of the specialty pharmaceutical company’s stock after selling 34,035 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Valeant Pharmaceuticals International were worth $1,414,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Gruss & Co. Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the 1st quarter worth $104,000. Harbor Advisors LLC bought a new position in shares of Valeant Pharmaceuticals International during the 1st quarter valued at $110,000. NEXT Financial Group Inc raised its holdings in shares of Valeant Pharmaceuticals International by 6.2% during the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after purchasing an additional 600 shares in the last quarter. Financial Architects Inc raised its holdings in shares of Valeant Pharmaceuticals International by 10.5% during the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,000 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Valeant Pharmaceuticals International by 33.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares in the last quarter. 50.48% of the stock is owned by institutional investors.

Several equities research analysts recently issued reports on VRX shares. Royal Bank Of Canada set a $19.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “sector perform” rating in a research note on Monday, June 19th. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 13th. ValuEngine downgraded shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a report on Sunday, July 30th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $23.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Five equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating to the company’s stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and an average target price of $17.57.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction dated Monday, August 21st. The stock was bought at an average price of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 14.62 on Tuesday. The stock has a 50 day moving average price of $13.97 and a 200 day moving average price of $13.35. Valeant Pharmaceuticals International, Inc. has a one year low of $8.31 and a one year high of $24.89. The firm’s market capitalization is $5.10 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. The firm had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.88) earnings per share. On average, equities analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/03/ontario-teachers-pension-plan-board-has-1-41-million-holdings-in-valeant-pharmaceuticals-international-inc-vrx.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.